NCT04678648RecruitingPhase 1
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
A Phase Ia/Ib, Open Label, Multi-center, Non-randomized Dose Escalation and Dose Expansion Study of RSC-1255 Alone or in Combination With Hydroxychloroquine in Patients With Advanced Solid Tumor Malignancies
Source: ClinicalTrials.gov · Last updated 23 Jun 2026
Brief summary (registry, in English)
RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after standard therapy, or have previously failed other therapies. The study has two phases. The purpose of Phase 1a (Dose Escalation) is to confirm the appropriate treatment dose and Phase 1b (Dose Expansion) is to characterize the safety and efficacy of RSC-1255.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 134 (estimated)
- First submitted
- 8 Dec 2020
- Start date
- 3 Mar 2021
- Primary completion date
- 15 Dec 2026
- Lead sponsor
- RasCal Therapeutics, Inc.
- NCT number
- NCT04678648
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 134
- From 3 Mar 2021 to the primary completion date, 15 Dec 2026
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants receiving cancer therapy at the time of enrollment.
- Has had a previous (within 2 years) or has a current malignancy other than the target cancer.
Other illness
- Any clinically significant disease or condition affecting a major organ system.
- Significant cardiovascular disease or electrocardiogram (ECG) abnormalities.
- Known Gilbert's disease.
- Grade 1 or higher nausea, vomiting, diarrhea at baseline due to underlying disease
Other
- Intermittent hypokalemia
Who the study is looking for
- Has pathologically confirmed advanced or metastatic malignancy characterized by one or more of the following:
- Participant is intolerant of existing therapy(ies) known to provide clinical benefit for their condition
- Malignancy is refractory to existing therapy(ies) known to potentially provide clinical benefit
- Malignancy has progressed on standard therapy
- Has evaluable or measurable tumor(s) in dose-escalation by standard radiological and/or laboratory assessments as applicable to their malignancy.
- Has adequate performance status (PS): Eastern Co-operative Oncology Group (ECOG).
- Is age ≥ 18 years.
- Has either tissue agnostic tumors and documented RAS mutations or with glioblastoma with or without mutation in RAS
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sarah Cannon, SCRI Oncology Partners - Health One Coordinator of this site? Confirm its status | Denver | United States | Recruiting |
| University of California, Los Angeles (UCLA) Department of Medicine - Hematology/Oncology Coordinator of this site? Confirm its status | Los Angeles | United States | Recruiting |
| Sarah Cannon, SCRI Oncology Partners Coordinator of this site? Confirm its status | Nashville | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.